Market Analysis and Insights: Global Sartans API Market
Due to the COVID-19 pandemic, the global Sartans API market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Valsartan accounting for % of the Sartans API global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Anti-Hypertension segment is altered to an % CAGR throughout this forecast period.
China Sartans API market size is valued at US$ million in 2021, while the US and Europe Sartans API are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Sartans API landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Sartans API include Pfizer, Novartis, Merck, AstraZeneca, Eli Lilly, Sanofi, Bristol-Myers Squibb, Bayer and GSK, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Sartans API Scope and Segment
Sartans API market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Sartans API market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Valsartan
Irbesartan
Telmisartan
Losartan
Others
Segment by Application
Anti-Hypertension
Anti-Viral
Others
By Company
Pfizer
Novartis
Merck
AstraZeneca
Eli Lilly
Sanofi
Bristol-Myers Squibb
Bayer
GSK
Teva Pharmaceutical
Xianju Pharma
Menovo
Tianyu Pharma
Starry Pharma
Huahai Pharmaceutical
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE